| Will treating diabetes with 11β-HSD1 inhibitors affect the HPA axis? | |
| | |
MedLine Citation:
|
PMID: 20594868 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Inhibitors of 11β-HSD1 are in clinical trials for the treatment of type 2 diabetes. These compounds act by decreasing the cortisol generated in liver and adipose tissue, and therefore reducing tissue-specific gluconeogenesis and fatty acid metabolism. However, there is concern that reduction in tissue-regenerated cortisol might decrease feedback to the hypothalamic-pituitary-adrenal (HPA) axis, resulting in upregulation of cortisol from the adrenal gland. This review considers evidence from 11β-HSD1 knockout and transgenic mice, inhibitor studies and results from clinical trials evaluating HPA axis biomarkers. It is clear that analysis of the HPA axis is not sufficiently detailed, and there is a need to understand the subtle changes in the axis associated with pulsatility, diurnal rhythm and stress. |
| | |
Authors:
|
Erika Harno; Anne White |
Related Documents
:
|
16571858 - Serum amyloid a: a marker of adiposity-induced low-grade inflammation but not of metabo... 10775808 - Insulin attenuates the stimulatory effects of tumor necrosis factor alpha on 11beta-hyd... 6482388 - Correlation of morphologic and biochemical observations in human lipomas. 6229798 - Pentose cycle flux and fatty acid synthesis in bovine adipose tissue slices incubated w... 10622278 - Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosi... 6818368 - Differences in vitamin a content of enteral feeding solutions following exposure to a p... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-06-30 |
Journal Detail:
|
Title: Trends in endocrinology and metabolism: TEM Volume: 21 ISSN: 1879-3061 ISO Abbreviation: Trends Endocrinol. Metab. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-04 Completed Date: 2011-01-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9001516 Medline TA: Trends Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 619-27 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Faculties of Life Sciences and Medical and Human Sciences, Manchester, Academic Health Sciences Centre, University of Manchester, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
11-beta-Hydroxysteroid Dehydrogenase Type 1
/
antagonists & inhibitors,
genetics,
metabolism* Aminopyridines / adverse effects, pharmacology*, therapeutic use Animals Diabetes Mellitus, Type 2 / drug therapy, genetics, metabolism Hydrocortisone / metabolism Hypoglycemic Agents / adverse effects, pharmacology*, therapeutic use Hypothalamo-Hypophyseal System / drug effects*, metabolism Mice Mice, Knockout Mice, Transgenic Pituitary-Adrenal System / drug effects*, metabolism Sulfonamides / adverse effects, pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide; 0/Aminopyridines; 0/Hypoglycemic Agents; 0/Sulfonamides; 50-23-7/Hydrocortisone; EC 1.1.1.146/11-beta-Hydroxysteroid Dehydrogenase Type 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potential drug interactions in elderly cancer patients.
Next Document: Label-free relative quantification of co-eluting isobaric phosphopeptides of insulin receptor substr...